For stock investors, the falling rates environment is now favoring one particular sector: consumer staples. As such, AMC stock dropped from nearly $35 in late 2016 to just over $10 in late 2017.

View NTLA's most recent analyst ratings, analyst estimates and price targets at MarketBeat. MarketBeat - Stock Market News and Research Tools logo. Intellia Therapeutics (NASDAQ:NTLA) Price Target and Consensus Rating Fundamental company data provided by Morningstar and Zacks Investment Research. Get today's Intellia Therapeutics Inc stock price and latest NTLA news as well as Intellia Therapeutics Inc real-time stock quotes, Zacks Investment Research. Intellia Therapeutics, Inc. (NASDAQ:NTLA) has 149 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange  Intellia Therapeutics Market Cap 2015-2019 | NTLA. Prices · Financials · Revenue 2019 is $0.72B. Compare NTLA With Other Stocks Stock Name, Country, Market Cap, PE Ratio.. Fundamental data from Zacks Investment Research, Inc. ODT: Get the latest Odonate Therapeutics stock price and detailed information Zacks.com featured highlights include: Odonate Therapeutics, Novavax, Beazer  NTLA for a $14.65 credit, down 57 cents, resulting in a 3.8% loss over 12 days. For my strategy portfolios, I require that stocks have a Zacks rank of 1 for entry,  10 hours ago Intellia Therapeutics (NASDAQ:NTLA) was downgraded by Zacks Investment Four equities research analysts have rated the stock with a hold 

Intellia Therapeutics, Inc. (NTLA) Shares March Higher, Can It Continue? By Zacks Investment Research - Nov 06, 2019. As of late, it has definitely been a great time to be an investor in Intellia Therapeutics, Inc. (NASDAQ:NTLA) . The stock has moved higher by 22.5% in the past month, while it is also above its 20

12/31/2019 · NTLA: Get the latest Intellia Therapeutics stock price and detailed information including NTLA news, historical charts and realtime prices. Intellia Therapeutics (NASDAQ:NTLA) was upgraded by Zacks Investment Research from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. The brokerage presently has a $15.00 price target on the stock. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group. TheStreet Ratings updates stock ratings daily. 11/9/2019 · Zacks Investment Research upgraded shares of Intellia Therapeutics (NASDAQ:NTLA) from a hold rating to a strong-buy rating in a research report released on Wednesday morning, Zacks.com reports. They currently have $15.00 target price on the stock. Check out our NTLA stock analysis, current NTLA quote, charts, and historical prices for Intellia Thera CS stock 12/25/2019 · Has Intellia Therapeutics (NTLA) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out. Intellia Therapeutics is one of 881 individual stocks in the Medical sector. Collectively, these companies sit at #2 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength 10/31/2019 · Find the latest Intellia Therapeutics, Inc. (NTLA) stock quote, history, news and other vital information to help you with your stock trading and investing.

Intellia Thera CS stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions.

As such, AMC stock dropped from nearly $35 in late 2016 to just over $10 in late 2017. Eldorado Gold (NYSE:EGO) and China Natural Resources (Nasdaq:CHNR) are both small-cap basic materials companies, but which is the superior stock? Zacks: Analysts Expect Sterling Bancorp (NYSE:STL) Will Post Quarterly Sales of $260.37 Million

Van Meerten Stock Picks. Jim Van Meerten's Daily Stock Picks highlights stocks you might want to consider for your portfolio, with Jim's editorials about current events and stock market commentary. Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Zacks News for NTLA. Has Intellia Therapeutics (NTLA) Outpaced Other Medical Stocks This Year? 12/25/19-10:30AM EST Zacks 

The companies announced the partnership Thursday and expect to finalize agreements for the new brand by the end […]

Analyzing Gilead Sciences (Nasdaq:GILD) stock? View GILD's stock price, price target, dividend, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. Get today's Intec Pharma Ltd stock price and latest NTEC news as well as Intec Pharma real-time stock quotes, technical analysis, full financials and more. Jd.com Inc Ads etfs funds price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report YY Inc. (YY): Free Stock Analysis Report Shopify Inc. (SHOP): Free Stock Analysis Report Salesforce.com Inc (CRM): Free Stock Analysis Report … Crispr Therapeutics Editas Medicine Intellia Therapeutics ERS Genomics Caribou BiosciencesTop 10 Value Stocks To Watch Right Now | Best Stocks For 2019www-topstocks.com/top-10-value-stocks-to-watch-right-now.htmlZacks Investment Research downgraded shares of Targa Resources from a “buy” rating to a “hold” rating in a research report on Friday, August 24th. ValuEngine raised shares of Targa Resources from a “hold” rating to a “buy” rating in a… Zacks Investment Research currently has $19.00 target price on the stock. According to Zacks, “Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products primarily in the United States. Ultrapro Short QQQ Proshares etfs funds price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions.

Stocks Analysis by Zacks Investment Research covering: BTC/USD, Intellia Therapeutics Inc. Read Zacks Investment Research's latest article on Investing.com Their average twelve-month price target is $26.92, suggesting that the stock has a possible upside of 83.48%. The high price target for NTLA is $57.50 and the low price target for NTLA is $16.00. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus rating of "Buy." 12/27/2019 · Interactive chart for Intellia Therapeutics, Inc. (NTLA) – analyse all of the data with a huge range of indicators.